Sugi Predict

Sugi Predict / Compounds / SCHEMBL895759

SCHEMBL895759

SCHEMBL895759

CC(C)(C)OC(=O)N[C@H]1CC[C@H](C(=O)O)C1

nearest known ligand 0.82

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.82
▸ KDM1A O60341 1/20 0.50
▸ MAOB P27338 1/20 0.50
▸ CTSK P43235 2/20 0.47
▸ KMT2A Q03164 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ NFKB1 P19838 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ HSD11B1 P28845 2/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ GAA P10253 3/20 0.42
▸ DRD2 P14416 2/20 0.41
▸ EPHX1 P07099 1/20 0.41
▸ EPHX2 P34913 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182101 1.00 BTK (0.82) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL13253521 1.00 BTK (0.82) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL2564638 1.00 BTK (0.82) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL1662045 1.00 BTK (0.82) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL1299320 1.00 BTK (0.82) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL25648917 1.00 BTK (0.82) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL540505 1.00 BTK (0.82) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL7486096 1.00 BTK (0.82) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL262171 0.91 BTK (0.69) BTKKDM1AMAOBCTSKKMT2A
SCHEMBL30915791 0.91 BTK (0.69) BTKKDM1AMAOBCTSKKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117756677-A Preparation method of chiral trans-N-BOC-1-aminocyclopentane-3-carboxylic acid 上海馨远医药科技有限公司 2024-03-26 — — CN claimed
EP-4725560-A2 ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2026-04-15 — — EP disclosed
CN-117756677-B Preparation method of chiral trans-N-BOC-1-aminocyclopentane-3-carboxylic acid 上海馨远医药科技有限公司 2025-09-30 — — CN disclosed
CN-117756677-B Preparation method of chiral trans-N-BOC-1-aminocyclopentane-3-carboxylic acid 上海馨远医药科技有限公司 2025-09-30 — — CN disclosed
US-20250099600-A1 Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2025-03-27 — — US disclosed
WO-2025064788-A2 CCR5 CONJUGATES AND USES THEREOF CIDARA THERAPEUTICS, INC. (US) 2025-03-27 — — WO disclosed
US-12144865-B2 Antibody drug conjugates with enzymatically cleavable groups BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2024-11-19 — — US disclosed
EP-4406606-A2 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE G Bayer Pharma Aktiengesellschaft (DE) 2024-07-31 — — EP disclosed
CN-117756677-A Preparation method of chiral trans-N-BOC-1-aminocyclopentane-3-carboxylic acid 上海馨远医药科技有限公司 2024-03-26 — — CN disclosed
CN-117756677-A Preparation method of chiral trans-N-BOC-1-aminocyclopentane-3-carboxylic acid 上海馨远医药科技有限公司 2024-03-26 — — CN disclosed
US-7858737-B2 Heterogeneous foldamers containing α, β, and/or γ-amino acids WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2010-12-28 — — US disclosed
US-7858737-B2 Heterogeneous foldamers containing α, β, and/or γ-amino acids WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2010-12-28 — — US disclosed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 — — US disclosed
WO-2010049331-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 — — WO disclosed
US-7452893-B2 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists MERCK & CO., INC. (US) 2008-11-18 — — US disclosed
US-20080076783-A1 Cycloalkyl Keto Piperidine Tachykinin Receptor Antagonists MERCK & CO., INC. (US) 2008-03-27 — — US disclosed
US-20070293515-A1 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists MERCK SHARP & DOHME CORP. 2007-12-20 — — US disclosed
US-20070037829-A1 e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients MERCK & CO., INC. (US) 2007-02-15 — — US disclosed
EP-1656379-B1 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2007-01-10 — — EP disclosed
US-20050054658-A1 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists THOMPSON WAYNE (US) 2005-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293515-A1 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists GRIN2B, GRIN2A, GRIN1 BTK 2343/4885KDM1A 1384/4885MAOB 311/4885
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B BTK 2496/4885KDM1A 1805/4885MAOB 192/4885
US-20250099600-A1 Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates KIF18B, KIF18A, KIF5B BTK 4292/4885KDM1A 2272/4885MAOB 4008/4885
US-20070037829-A1 e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients GRIN2B, GRIN3A, GRIN2A BTK 4497/4885KDM1A 2780/4885MAOB 335/4885
US-12144865-B2 Antibody drug conjugates with enzymatically cleavable groups KIFC1, KIF2C, KIF5B BTK 2364/4885KDM1A 1070/4885MAOB 3461/4885
US-20080076783-A1 Cycloalkyl Keto Piperidine Tachykinin Receptor Antagonists TACR1, TACR2, NPSR1 BTK 4766/4885KDM1A 1021/4885MAOB 1274/4885
US-20050054658-A1 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists GRIN2B, GRIN1, GRIN2A BTK 2723/4885KDM1A 2922/4885MAOB 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.